×
About 186 results

ALLMedicine™ Coronary Drug-eluting Stent Center

Research & Reviews  89 results

Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable pol...
https://doi.org/10.1097/MCA.0000000000000949
Coronary Artery Disease; Sethi A, Kodumuri V et. al.

Sep 8th, 2020 - Improvements in coronary drug-eluting stent technology has focused on reducing the long-term complications associated with the effects of the residual footprint on the vessel wall. Although many of the newer stents have exhibited noninferiority to...

End-stage renal disease as an independent risk factor for in-hospital mortality after c...
https://doi.org/10.1002/ccd.28929
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions REFERENCES; Dunn AN, Huded C et. al.

May 18th, 2020 - We sought to compare in-hospital outcomes between patients with and without end-stage renal disease (ESRD) undergoing coronary drug-eluting stent (DES) placement and to model risk of in-hospital adverse postpercutaneous coronary intervention (PCI)...

Coronary Drug-Eluting Stent Infection Complicated by Coronary Artery Aneurysm and Purul...
https://doi.org/10.1016/j.cjca.2020.01.007
The Canadian Journal of Cardiology; Riku S, Suzuki S et. al.

May 14th, 2020 - Coronary stent infection is considered to be a rare but catastrophic complication of percutaneous coronary intervention. In this report, we present a 72-year-old man who developed a coronary stent infection complicated by coronary aneurysm and pur...

Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting St...
https://doi.org/10.1055/s-0040-1709520
Thrombosis and Haemostasis; Dai C, Chen Z et. al.

May 5th, 2020 - Cilostazol-based dual antiplatelet therapy (DAPT) is widely used in patients with aspirin intolerance after coronary drug-eluting stent (DES) implantation in China. However, this empirical strategy is not recommended or even mentioned in Chinese o...

Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coate...
https://doi.org/10.1016/j.jcin.2018.11.040
JACC. Cardiovascular Interventions; Ali RM, Abdul Kader MASK et. al.

Mar 22nd, 2019 - The aim of this randomized controlled trial was to investigate a novel sirolimus-coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB). Treatment of coronary in-stent restenosis (ISR) remains challenging. PCBs ar...

see more →

Guidelines  1 results

Quality Improvement Guidelines for Mesenteric Angioplasty and Stent Placement for the Treatm...
https://www.jvir.org/article/S1051-0443(17)31070-9/fulltext
Pillai, A.,et al.

Apr 30th, 2018 - The membership of the Society of Interventional Radiology (SIR) Standards of Practice Committee represents experts in a broad spectrum of interventional procedures from the private and academic sectors of medicine. Generally, Standards of Practice.

see more →

Clinicaltrials.gov  93 results

Ultrathin biodegradable polymer sirolimus-eluting stent versus contemporary durable pol...
https://doi.org/10.1097/MCA.0000000000000949
Coronary Artery Disease; Sethi A, Kodumuri V et. al.

Sep 8th, 2020 - Improvements in coronary drug-eluting stent technology has focused on reducing the long-term complications associated with the effects of the residual footprint on the vessel wall. Although many of the newer stents have exhibited noninferiority to...

End-stage renal disease as an independent risk factor for in-hospital mortality after c...
https://doi.org/10.1002/ccd.28929
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions REFERENCES; Dunn AN, Huded C et. al.

May 18th, 2020 - We sought to compare in-hospital outcomes between patients with and without end-stage renal disease (ESRD) undergoing coronary drug-eluting stent (DES) placement and to model risk of in-hospital adverse postpercutaneous coronary intervention (PCI)...

Coronary Drug-Eluting Stent Infection Complicated by Coronary Artery Aneurysm and Purul...
https://doi.org/10.1016/j.cjca.2020.01.007
The Canadian Journal of Cardiology; Riku S, Suzuki S et. al.

May 14th, 2020 - Coronary stent infection is considered to be a rare but catastrophic complication of percutaneous coronary intervention. In this report, we present a 72-year-old man who developed a coronary stent infection complicated by coronary aneurysm and pur...

Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting St...
https://doi.org/10.1055/s-0040-1709520
Thrombosis and Haemostasis; Dai C, Chen Z et. al.

May 5th, 2020 - Cilostazol-based dual antiplatelet therapy (DAPT) is widely used in patients with aspirin intolerance after coronary drug-eluting stent (DES) implantation in China. However, this empirical strategy is not recommended or even mentioned in Chinese o...

Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coate...
https://doi.org/10.1016/j.jcin.2018.11.040
JACC. Cardiovascular Interventions; Ali RM, Abdul Kader MASK et. al.

Mar 22nd, 2019 - The aim of this randomized controlled trial was to investigate a novel sirolimus-coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB). Treatment of coronary in-stent restenosis (ISR) remains challenging. PCBs ar...

see more →

News  3 results

BIOFLOW V: Orsiro outperforms Xience stent
https://www.mdedge.com/cardiology/article/178950/interventional-cardiology-surgery/bioflow-v-orsiro-outperforms-xience
Susan London

Nov 5th, 2018 - SAN DIEGO – Seemingly nuanced differences between drug-eluting stents can translate to substantial differences in clinical outcomes longer term, updated results of the BIOFLOW V randomized trial reported at the Transcatheter Cardiovascular Therape.

Reigning Coronary DES King Matches Its Predecessor
https://www.mdedge.com/internalmedicine/article/37228/cardiology/reigning-coronary-des-king-matches-its-predecessor
Mitchel L. Zoler

Aug 30th, 2011 - PARIS – The current master of the coronary drug-eluting stent universe, the everolimus-eluting stent, finally proved itself fully worthy of its position, matching the efficacy and safety performance of its predecessor, the sirolimus-eluting corona.

Coronary Drug-Eluting Stent Safety Diminishes Over Time
https://www.medpagetoday.com/cardiology/pci/12228

Dec 18th, 2008 - Action Points Explain to interested patients that this study suggests that both drug-eluting and bare-metal stents have good long-term safety profiles. Explain to patients who ask that a number of factors influence the choice of stent type. Explai...

see more →